TY - T1的雌激素替代疗法对响应的影响他克林阿尔茨海默氏症患者JF -神经学乔-神经病学SP - 1580 LP - 1584 - 10.1212 / WNL.46.6.1580六世- 46 - 6非盟-朗美国施耐德盟-马丁·r·大学法首页洛非盟-维克多·w·亨德森盟贾尼斯·m·佛塔Y1 - 1996/06/01 UR - //www.ez-admanager.com/content/46/6/1580.abstract N2 -目的:检查雌激素替代疗法(ERT)是否会影响临床和认知反应他克林在阿尔茨海默病(AD)的女性。设计:一个报告显示,随机、双盲、安慰剂对照,与这些相应平行的组织,多中心临床试验的他克林子群的女性接受随机化之前接受方。病人:女性轻度moderate-stage广告,至少50岁,进入之前报道审判。干预:随机分配安慰剂或三个他克林ascending-dosage方案之一:最大剂量为80毫克/天,120 mg / d,或160毫克/天。结果测量:阿尔茨海默病评定量表-认知量表(ADASc),临床医生的印象改变(研究所),面访细微精神状态检查(MMSE)、照顾者的印象改变(CIC)。结果:318名妇女接受ERT可评价的数据为14.5%。Women completing the trial taking ERT and tacrine improved more than women not receiving ERT who were randomly assigned to tacrine or to placebo as assessed by the ADASc (p < 0.01), the CIBI (p = 0.02), the CIC (p = 0.006), and the MMSE (p = 0.07). They improved significantly on the ADASc (p = 0.01) using an intent-to-treat analysis. Conclusions: Prior and continuing ERT may enhance response to tacrine in women with AD. Randomized trials are needed. NEUROLOGY 1996;46: 1580-1584 ER -